RxDoctor Payments Data

Oral Waldo, MD

Cardiovascular Disease · West Palm Beach, FLNPI 1124313176

Payments from drug & device makers

$7,281in general payments, 2019–2025

Across 169 payments — averaging $43.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$1K
  • Johnson & Johnson$343
  • Amgen$328
  • Heartflow, Inc.$290
  • Novo Nordisk$252
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$6,90595%
  • Education$3615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,281 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$183,764
Medicare patients
614
Services billed
1,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$40,470
EntrestoSacubitril/Valsartan14$14,718
Atorvastatin Calcium162$1,374
Metoprolol Succinate79$848
Carvedilol55$536
Metoprolol Tartrate33$449
Hydralazine Hcl21$335
Pravastatin Sodium21$310
Losartan Potassium27$210
Amlodipine Besylate31$150
Isosorbide Mononitrate ErIsosorbide Mononitrate14$128
Amiodarone Hcl13$122
Rosuvastatin Calcium15$109
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$88
Furosemide12$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$40,47037 claims
NovartisEntresto$215$14,71814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →